Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicholas Piramal Says Contract Research Progressing, Avecia Unit Profitable

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Nicholas Piramal said its growing contract research business, forecast to be a separately listed unit by June, has four potential compounds in Phase I to Phase II trials while its Avecia Pharmaceuticals unit has turned profitable

You may also be interested in...



PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms

NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country

PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms

NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country

Lilly, Merck Deals Mark Start Of New Era For Indian Drug Firms – PharmAsia News Spotlight

MUMBAI - A new patent law to protect intellectual property and in-depth experience in clinical trials and manufacturing has helped Indian drug firms such as Piramal Healthcare become equal partners with multinational counterparts in sharing risks, costs and profits, according to a senior company executive

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel